


NIH Consensus Statement

Volume 17, Number 4
November 1-3, 2000



Adjuvant Therapy for Breast Cancer

NATIONAL INSTITUTES OF HEALTH
Office of the Director

About the NIH Consensus Development Program

NIH Consensus Development Conferences are convened to evaluate available scientific information and resolve safety and efficacy issues related to a biomedical technology. The resultant NIH Consensus Statements are intended to advance understanding of the technology or issue in question and to be useful to health professionals and the public.

NIH Consensus Statements are prepared by nonadvocate, non-Federal panels of experts, based on (1) presentations by investigators working in areas relevant to the consensus questions during a 2-day public session, (2) questions and statements from conference attendees during open discussion periods that are part of the public session, and (3) closed deliberations by the panel during the remainder of the second day and morning of the third. This statement is an independent report of the consensus panel and is not a policy statement of the NIH or the Federal Government.

Reference Information

For making bibliographic reference to this consensus statement, it is recommended that the following format be used, with or without source abbreviations, but without authorship attribution:

Adjuvant Therapy for Breast Cancer. NIH Consensus Statement 2000 November 1-3; 17(4): 1-35.

Publications Ordering Information

NIH Consensus Statements, NIH Technology Assessment Statements, and related materials are available by writing to the NIH Consensus Program Information Center, P.O. Box 2577, Kensington, MD 20891; by calling toll-free 1-888-NIH-CONSENSUS (888-644-2667); or by visiting the NIH Consensus Development Program home page at <http://consensus.nih.gov> on the World Wide Web.5



NIH Consensus Statement

Volume 17, Number 4

November 1–3, 2000

Date of original release: November 3, 2000

Adjuvant Therapy for Breast Cancer

This statement reflects the panel’s assessment of medical knowledge available at the time the statement was written. Thus, it provides a “snapshot in time” of the state of knowledge of the conference topic. When reading the statement, keep in mind that new knowledge is inevitably accumulating through medical research.



NATIONAL INSTITUTES OF HEALTH
Office of the Director

Disclosure Statement

All of the panelists who participated in this conference and contributed to the writing of this consensus statement were identified as having no financial or scientific conflict of interest, and all signed conflict of interest forms attesting to this fact. Unlike the expert speakers who present scientific data at the conference, the individuals invited to participate on NIH consensus panels are selected specifically because they are not professionally identified with advocacy positions with respect to the conference topic or with research that could be used to answer any of the conference questions.

Abstract

Objective

To provide health care providers, patients, and the general public with a current consensus on various issues related to the use of adjuvant therapy for breast cancer.

Participants

A nonfederal, nonadvocate, 14-member panel representing the fields of oncology, radiology, surgery, pathology, statistics, public health, health policy, and the public; 30 experts in medical oncology, molecular oncology, biostatistics, epidemiology, surgical oncology, and clinical trials who presented data to the consensus panel; a conference audience of approximately 1,000.

Evidence

The literature was searched using MEDLINE and an extensive bibliography of references was provided to the panel. Experts prepared abstracts with relevant citations from the literature. Scientific evidence was given precedence over clinical anecdotal experience.

Consensus Process

The panel, answering predefined questions, developed their conclusions based on the scientific evidence presented in open forum and the scientific literature. The panel composed a draft statement that was read in its entirety and circulated to the experts and the audience for comment. Thereafter, the panel resolved conflicting recommendations and released a revised statement at the end of the conference. The panel finalized the revisions within a few weeks after the conference. The draft statement was made available on the World Wide Web immediately following its release at the conference and was updated with the panel's final revisions.

Conclusions

Decisions regarding adjuvant hormonal therapy should be based on the presence of hormone receptor protein in tumor tissues. Adjuvant hormonal therapy should be offered only to women whose tumors express hormone receptor protein.

Because adjuvant polychemotherapy improves survival, it should be recommended to the majority of women with localized breast cancer regardless of nodal, menopausal, or hormone receptor status. The inclusion of anthracyclines in adjuvant chemotherapy regimens produces a small but statistically significant improvement in survival over non-anthracycline-containing regimens.

Available data are currently inconclusive regarding the use of taxanes in adjuvant treatment of node-positive breast cancer. The use of adjuvant dose-intensive chemotherapy regimens in high-risk breast cancer and of taxanes in node-negative breast cancer should be restricted to randomized trials. Ongoing studies evaluating these treatment strategies should be supported to determine if they have a role in adjuvant treatment.

Studies to date have included few patients older than 70 years. There is a critical need for trials to evaluate the role of adjuvant chemotherapy in these women.

There is evidence that women with a high risk of loco-regional tumor recurrence after mastectomy benefit from postoperative radiotherapy. This high-risk group includes women with four or more positive lymph nodes or an advanced primary cancer. Currently, the role of post-mastectomy radiotherapy for patients with one to three positive lymph nodes remains uncertain and should be tested in a randomized controlled trial.

Individual patients differ in the importance they place on the risks and benefits of adjuvant treatments. Quality-of-life needs to be evaluated in selected randomized clinical trials

to examine the impact of the major acute and long-term side effects of adjuvant treatments, particularly premature menopause, weight gain, mild memory loss, and fatigue. Methods to support shared decision-making between patients and their physicians have been successful in trials; they need to be tailored for diverse populations and should be tested for broader dissemination.

Introduction

Each year, more than 180,000 women in the United States are diagnosed with breast cancer, the most common type of noncutaneous cancer among women in this country. If current breast cancer rates remain constant, a woman born today has a one in ten chance of developing breast cancer.

Because of continuing research into new treatment methods, women with breast cancer now have more treatment options and a better chance of long-term survival than ever before. The primary treatment of localized breast cancer is either breast-conserving surgery and radiation or mastectomy with or without breast reconstruction. Systemic adjuvant therapies that are designed to eradicate microscopic deposits of cancer cells that may have spread or metastasized from the primary breast cancer have been demonstrated to increase a woman's chance of long-term survival.

Systemic adjuvant therapies include chemotherapy (anticancer drugs) and hormone therapy. In addition to these systemic therapies, radiotherapy is used in selected cases as a local adjuvant treatment to destroy breast cancer cells that remain in the chest wall or regional lymph nodes after mastectomy.

The rapid pace of discovery in this area continues to expand the knowledge base from which informed treatment decisions can be made. The purpose of this conference was to establish a consensus regarding the use of adjuvant therapy for breast cancer and to communicate that consensus to clinicians, patients, and the general public. After reading relevant literature and attending a day and a half of presentations and audience discussion, an independent, non-Federal consensus development panel weighed the scientific evidence and drafted a statement that was presented to the conference audience on the third day. The consensus development panel's statement addresses the following key questions:

- Which factors should be used to select systemic adjuvant therapy?

- For which patients should adjuvant hormonal therapy be recommended?
- For which patients should adjuvant chemotherapy be recommended? Which agents should be used, and at what dose or schedule?
- For which patients should post-mastectomy radiotherapy be recommended?
- How do side effects and quality-of-life issues factor into individual decision-making about adjuvant therapy?
- What are promising new research directions for adjuvant therapy?

This conference was sponsored by the National Cancer Institute and the NIH Office of Medical Applications of Research. The co-sponsors included the National Institute of Nursing Research and the NIH Office of Research on Women's Health.

Which Factors Should Be Used To Select Systemic Adjuvant Therapy?

The selection of systemic adjuvant therapy is based on prognostic and predictive factors. Prognostic factors are measurements available at diagnosis or time of surgery that, in the absence of adjuvant therapy, are associated with recurrence rate, death rate, or other clinical outcome. Predictive factors are measurements associated with the degree of response to a specific therapy. For example, a demonstration of hormone receptors in tumor cells predicts the response to hormonal therapy. Any factor has the potential to be both prognostic and predictive, and a factor's importance depends on both the clinical endpoint and on the method of treatment comparison.

Prognostic and predictive factors fall into three categories: patient characteristics that are independent of the disease (such as age); disease characteristics (such as tumor size and histologic type); and biomarkers (measurable parameters in tissues, cells, or fluids), such as hormone receptor status, progesterone receptor status, and measures of cell turnover. Accepted prognostic and predictive factors include age, tumor size, axillary node status, histological tumor type, standardized pathologic grade, and hormonal-receptor status.

The median age for the diagnosis of breast cancer is between the ages of 60 and 65 years. Some younger women (particularly under 35 years) have a more aggressive form of the disease, characterized by larger tumors of higher grade with vascular invasion. Elderly women (over 70 years) with breast cancer frequently have hormone receptor protein in their malignant tissue, suggesting a more indolent tumor pattern and a high likelihood of response to hormonal therapy.

Race appears to be a prognostic but not predictive factor. In contrast to white women, black breast cancer patients are generally younger, often have larger tumors at diagnosis, and a smaller percentage have hormone receptors in their tumor tissue. These factors contribute to a poorer prognosis. In cases of similar clinical presentation, however, adjuvant

treatment confers similar benefits to black and white women. Research on the benefits and risks of adjuvant therapy in Hispanic, Asian, and Native American women is needed.

Novel technologies (such as tissue and expression microarrays and proteomics) present exciting potential, but their integration into clinical practice will depend on the proper design and analysis of clinical investigations. The same is true for overexpression of HER-2/neu, p53 status, histologic evidence of vascular invasion, and quantitative parameters of angiogenesis. These have been extensively studied clinically and biologically, but do not have an established role in patient management. For example, although overexpression/amplification of HER-2/neu is associated with an adverse outcome in node-positive patients and may predict the response to therapy, laboratory methods and the reporting of results require standardization before its predictive performance can be established.

The development of immunohistochemical and molecular methods to identify occult cancer cells (i.e., micrometastases) in histologically tumor-free axillary lymph nodes or bone marrow has raised questions as to whether such findings should alter the clinical stage and become a further indication for systemic adjuvant therapy. At present, the clinical significance of these findings remains uncertain, and they require assessment in prospective clinical trials before they directly alter patient management.

It is essential that the value of predictive and prognostic factors be evaluated in well-designed clinical studies that are based on standardized protocols and have sufficient statistical power. Because these standards are infrequently met, very few new prognostic or predictive factors have been validated in the last 10 years, and future progress will depend on greater attention to these standards. Promising pilot studies should be followed by a validation phase, during which alternative assays for the biomarker are evaluated in a head-to-head comparison and prognostic/predictive value is studied. Since no single study will have sufficient power to properly evaluate predictive value, results from these trials should be combined.

For Which Patients Should Adjuvant Hormonal Therapy Be Recommended?

The decision whether to recommend adjuvant hormonal therapy should be based on the presence of hormone receptors, as assessed by immunohistochemical staining of breast cancer tissue. If the available tissue is insufficient to determine hormone receptor status, it should be considered as being positive, particularly in postmenopausal women. The small subset of women whose tumors lack hormone receptor protein but contain progesterone receptor also appear to benefit from hormonal therapy. The presence or absence of HER-2/neu overexpression should not influence the decision to recommend hormonal therapy.

The goal of hormonal therapy is to prevent breast cancer cells from receiving stimulation from estrogen. Such stimulation occurs primarily in tumors that contain hormone receptor protein. Estrogen deprivation can be achieved by (a) blocking the receptor through the use of drugs, such as tamoxifen; (b) suppression of estrogen synthesis through the administration of aromatase inhibitors (e.g., anastrozole) in postmenopausal women or LHRH agonists (e.g., goserelin) in premenopausal women; or (c) destruction of the ovaries through surgery or external beam radiation therapy. The administration of cytotoxic chemotherapy may indirectly accomplish this same effect by damaging estrogen-producing cells in the ovaries.

Adjuvant hormonal therapy should be recommended to women whose breast tumors contain hormone receptor protein, regardless of age, menopausal status, involvement of axillary lymph nodes, or tumor size. While the likelihood of benefit correlates with the amount of hormone receptor protein in tumor cells, patients with any extent of hormone receptor in their tumor cells may still benefit from hormonal therapy. Such treatment has led to substantial reductions in the likelihood of tumor recurrence, second primary breast cancer, and death persisting for at least 15 years of follow-up. Possible exceptions to this recommendation include

premenopausal women with tumors less than 10 mm in size who wish to avoid the symptoms of estrogen deprivation or elderly women with similarly sized cancers who have a history of venous thromboembolic episodes.

Tamoxifen is the most commonly used form of hormonal therapy. Randomized trials and a meta-analysis have shown that 5 years of tamoxifen are superior to 1 to 2 years of such treatment. Currently, there are no convincing data that justify the use of tamoxifen for longer than 5 years outside the setting of a clinical trial. Although tamoxifen has been associated with a slight but definite increased risk of endometrial cancer and venous thromboembolism, the benefit of tamoxifen treatment far outweighs its risks in the majority of women. Neither transvaginal ultrasonography nor endometrial biopsies are indicated as screening maneuvers for endometrial cancer in asymptomatic women taking tamoxifen. Tamoxifen may be combined with combination chemotherapy, particularly in premenopausal women; such combinations may further reduce the risk of recurrence. There are no data to support the use of raloxifene or aromatase inhibitors as adjuvant hormonal therapy at this time.

For hormone receptor positive premenopausal patients, alternative strategies of hormonal therapy, which are used far less frequently in the United States, include ovarian ablation through surgery, radiation therapy to the ovaries, or chemical suppression of ovarian function. Ovarian ablation appears to produce a similar benefit to some chemotherapy regimens. Combining ovarian ablation with chemotherapy has not been shown to provide an additional advantage to date. The value of combining hormonal therapies has not yet been adequately explored.

Hormonal adjuvant therapy should not be recommended to women whose breast cancers do not express hormone receptor protein. Randomized clinical trials have not yet shown that such treatment substantially reduces the likelihood of recurrence or, in the case of tamoxifen, diminishes the likelihood of contralateral breast cancer.

For Which Patients Should Adjuvant Chemotherapy Be Recommended? Which Agents Should Be Used, and at What Dose or Schedule?

Over the past decade, data have emerged that more clearly define the subpopulations of women with localized breast cancer for whom adjuvant chemotherapy is indicated as a standard component of treatment. Chemotherapy has been shown to substantially improve the long-term, relapse-free, and overall survival in both premenopausal and postmenopausal women up to age 70 years with node-positive and node-negative disease.

Randomized clinical trials have attempted to define optimal chemotherapy regimens, doses, and schedules in the adjuvant treatment of breast cancer. These studies, along with the results of overview analyses, permit a number of conclusions to be drawn.

The administration of polychemotherapy (≥ 2 agents) is superior to single agents. Four to six courses of treatment (3 to 6 months) appear to provide optimal benefit, with the administration of additional courses adding to toxicity without substantially improving overall outcome. However, definitive data on the benefits of more prolonged treatment are lacking and future research is needed to directly address this clinically relevant issue.

Anthracyclines (such as doxorubicin and epirubicin) have been used as components of adjuvant polychemotherapy for breast cancer. Available data indicate that adjuvant chemotherapy regimens that include an anthracycline result in a small but statistically significant improvement in survival compared to nonanthracycline-containing programs. There is no evidence for excessive cardiac toxicity in women without significant preexisting heart disease treated with anthracyclines at the cumulative doses utilized in standard adjuvant programs. In clinical practice, the decision to use an anthracycline in an individual patient should take into consideration the potential survival benefits versus specific concern about additional toxicity.

Randomized trials have demonstrated threshold dose effects for two of the most active chemotherapeutic agents, doxorubicin (A) and cyclophosphamide (C). These two drugs are frequently administered together (AC) and appear to result in a comparable survival outcome, whether given preoperatively or postoperatively. However, AC has not been compared to cyclophosphamide/doxorubicin/5-fluorouracil (CAF) or cyclophosphamide/epirubicin/5-fluorouracil (CEF). There is a need for future studies to address the issue of defining the optimal use of anthracycline-based therapy.

There is currently no convincing evidence to demonstrate that more dose-intensive treatment regimens (e.g., high-dose chemotherapy with peripheral stem cell support) result in improved outcomes compared to the administration of polychemotherapy programs at standard dose levels. Such stem cell-support treatment strategies should not be offered outside the setting of a randomized clinical trial.

Taxanes (docetaxel, paclitaxel) have recently been demonstrated to be among the most active agents in the treatment of metastatic breast cancer. As a result, several studies have explored the clinical utility of adding these drugs to standard doxorubicin/cyclophosphamide treatment programs in the adjuvant treatment of node-positive, localized breast cancer. Although a number of such trials have completed accrual and others remain in progress, currently available data are inconclusive and do not permit definitive recommendations regarding the impact of taxanes on either relapse-free or overall survival. There is no evidence to support the use of taxanes in node-negative breast cancer outside the setting of a clinical trial.

Available data demonstrate that chemotherapy and tamoxifen are additive in their impact on survival when employed as adjuvant treatment of breast cancer. Therefore, most patients with hormone receptor positive tumors who are receiving chemotherapy should receive tamoxifen.

At the present time, there are no convincing data to support the use of any known biological factor in selecting a specific adjuvant chemotherapy regimen in breast cancer. Future

prospective studies are needed to determine if such factors in an individual patient (e.g., HER-2/neu overexpression) should influence the choice of adjuvant cytotoxic therapy.

Despite the favorable impact of adjuvant chemotherapy on long-term survival in breast cancer, it is important to determine whether there are specific patient populations for whom it is reasonable to avoid the administration of cytotoxic chemotherapy. Unfortunately, very limited information is available to answer this important question. On the basis of available data, it is accepted practice to offer cytotoxic chemotherapy to most women with lymph node metastases or with primary breast cancers larger than 1 cm in diameter (both node-negative and node-positive). For women with node-negative cancers less than 1 cm in diameter, the decision to consider chemotherapy should be individualized.

Similarly, in patients with small, node-negative breast cancers with favorable histologic subtypes, such as tubular and mucinous cancers, retrospective data support long-term survival following primary therapy without the need for adjuvant chemotherapy.

There are limited data to define the optimal use of adjuvant chemotherapy for women more than 70 years of age. It is likely that there is a survival benefit associated with the administration of chemotherapy in this patient population. There is legitimate concern, however, regarding the toxicity associated with cytotoxic regimens in this population. In addition, existing comorbid medical conditions and mortality from noncancer causes will influence the overall benefits in this group of women. The decision to treat women over the age of 70 with adjuvant chemotherapy will need to consider these factors. Increased participation of women over 70 in randomized clinical trials and studies specifically addressing the value and tolerance of adjuvant chemotherapy in these women are urgently needed.

For Which Patients Should Post-Mastectomy Radiotherapy Be Recommended?

The standard of care for breast conservation includes surgery followed by breast radiotherapy. Before the advent of effective adjuvant chemotherapy, post-mastectomy radiotherapy was commonly employed. Interest in this approach was revived after several studies identified patient subgroups with 20 to 40 percent rates of locoregional recurrence after mastectomy and chemotherapy. These subgroups, which included women with four or more positive lymph nodes or an advanced primary tumor (a tumor of 5 cm or greater or a tumor invading the skin or adjacent musculature), were thought most likely to benefit from a course of post-mastectomy radiotherapy.

Recent randomized controlled trials have demonstrated superior tumor control and overall survival rates with the addition of post-mastectomy radiotherapy. A recent meta-analysis of more than 22,000 women comparing adjuvant radiotherapy to no radiotherapy reported an improvement in locoregional tumor control rates from 70 percent to 90 percent. This resulted in a significant improvement in the overall survival rate and in the disease-specific survival rate after a followup time of 20 years. These findings lend support to the concept that improving locoregional tumor control rates in breast cancer can lead to an improvement in survival rates.

The potential benefits of post-mastectomy radiotherapy must be weighed against both the acute and long-term side effects of this therapy. The same meta-analysis documented an excess of non-breast cancer deaths, the majority of which were vascular in nature. These deaths were probably related to the high radiotherapy doses received by the heart and great vessels through the use of outdated radiotherapy techniques. Contemporary radiotherapy delivery employing image-based planning has substantially reduced the radiotherapy dose received by these structures. Although the duration of followup of women treated with modern techniques is more limited, preliminary data show no apparent

increase in vascular deaths. Post-mastectomy radiotherapy, however, is associated with an increased risk of arm edema.

There is evidence that women with a high risk of loco-regional tumor recurrence after mastectomy will benefit from postoperative radiotherapy. This high-risk group includes women with four or more positive lymph nodes or an advanced primary tumor. Post-mastectomy radiotherapy must be coordinated with adjuvant multiagent chemotherapy and/or hormonal therapy. Radiotherapy should not be delivered concurrently with anthracycline chemotherapy and should be delivered within the first 6 months following mastectomy. In most circumstances, combined modality adjuvant therapy begins with several courses of chemotherapy. Radiotherapy, as part of such treatment programs, should be delivered with modern techniques designed to reduce the volume of heart and great vessels receiving radiotherapy. At this time, the role of post-mastectomy radiotherapy for women with one to three positive lymph nodes remains uncertain and is being examined in a randomized clinical trial.

How Do Side Effects and Quality-of-Life Issues Factor into Individual Decision-Making About Adjuvant Therapy?

Adjuvant therapy decisions are complicated by marginal differences in treatment results and risk-benefit profiles, balancing acute effects with long-term outcomes. Individual patients differ in the value they place on these issues. Retrospective studies report that women may be willing to undergo treatment for as little as a 1 to 2 percent improvement in the probability of survival. Clear communication of benefits and risks is an essential component in enabling as informed a joint treatment decision as possible. Absolute and relative benefits and risks of therapy must be discussed openly.

Acute, Long-Term and Late Medical Effects of Adjuvant Therapy

Adjuvant Chemotherapy

Studies to date have documented a range of acute and late side effects of adjuvant chemotherapy that have the potential for significantly affecting patients' quality of life. Most acute side effects (e.g., nausea and vomiting, mucositis, hair loss, neutropenia) occur in varying degrees in the different chemotherapy regimens and resolve after treatment completion. This also seems to be true for psychological distress. Several randomized studies have found that the psychological distress patients experience is greater during more toxic adjuvant chemotherapy treatment, resolving soon after treatment completion. Similarly, 1 to 3 years after completing treatment, the distress levels of cancer survivors who had undergone any of the different adjuvant chemoendocrine therapies equal the levels of those who had received no further adjuvant therapy.

The simultaneous combination of chemotherapy plus tamoxifen is associated with an increased risk of thromboembolism when compared to tamoxifen alone. Premature menopause, weight gain, and fatigue are the most frequent long- and short-term problems that have been documented.

Several small studies have documented mild cognitive problems, such as those in memory, with precise levels of prevalence and severity yet to be determined. There is also a very small increase in the risk of treatment-related second malignancies and cardiac disease.

*Adjuvant Hormone Therapy:
Tamoxifen and Ovarian Ablation*

Hot flashes and vaginal discharge have been the most common side effects attributed to tamoxifen. Tamoxifen is associated with a small, increased risk of endometrial cancer, pulmonary emboli, and deep vein thrombosis, particularly for women 50 years old or older. The benefits, however, far outweigh the risks. Tamoxifen has not been associated with an increase in depression, weight gain, nausea and vomiting, diarrhea, or problems in sexual functioning. As with adjuvant chemotherapy, ovarian ablation is associated with the development of premature menopause and its associated symptoms including osteoporosis.

Decision-making in Adjuvant Therapy for Breast Cancer

Communication between patients and their physicians is the primary vehicle through which complex treatment decisions are made. This communication will likely be facilitated through the use of decision aids, and well-designed patient information materials about the medical condition or procedure, treatment side effects, probabilities associated with health outcomes, and impact on quality of life. Findings from current research suggest that decision aids improve patients' knowledge about treatment options, reduce patients' anxiety about treatment decisions and enhance their comfort with treatment choices, and stimulate patients to play a more active role in joint decision-making with their physicians.

What Are Promising New Research Directions for Adjuvant Therapy?

During the past decade, major advances in adjuvant treatment of breast cancer have resulted from analyses of large prospective randomized trials. In the United States, however, fewer than 3 percent of cancer patients are entered in clinical trials. To achieve continued improvements in adjuvant treatment, efforts should be made to improve patient and physician participation in these studies. A number of important questions remain to be answered.

Randomized clinical trials should be conducted to better define the risks and benefits of continuing tamoxifen therapy beyond 5 years. Studies are also needed to expand experience with ovarian ablation, to explore the value of combined hormonal therapy, and to determine whether optimal hormonal therapy is equivalent, superior, or additive to chemotherapy in premenopausal women whose tumors express hormone receptor protein. The risks and benefits of new, selective estrogen receptor modulators (SERMs) and aromatase inhibitors should also be examined in the adjuvant setting.

Randomized clinical trials evaluating the roles of high dose chemotherapy and taxanes need to be completed to determine whether these treatments have a role in the standard management of breast cancer. Additional studies are also needed to determine the importance of variations in the doses and schedules of the drugs used in chemotherapy regimens that are currently accepted as being standard. A particular emphasis should be placed on carefully designed studies to determine the clinical and biological characteristics that may more accurately predict the effectiveness of specific adjuvant treatments in individual patients. As yet unproven treatments that must be critically evaluated in prospective trials in the adjuvant setting include trastuzumab, bisphosphonates, and newer chemotherapeutic and biologic agents.

To date, prospective trials of adjuvant therapy have failed to include sufficient numbers of women older than 70 years. Studies need to be designed that will determine the effectiveness of adjuvant therapies in this group of women.

The role of post-mastectomy radiotherapy in women with 1 to 3 positive lymph nodes needs to be determined. Investigators should continue to explore the importance of risk factors for recurrence after mastectomy to improve the selection of patients who may benefit from adjuvant radiotherapy. To maximize the possible benefit of adjuvant radiotherapy, new radiation techniques should be developed that further reduce the radiation dose to normal tissues, such as the heart and lungs.

Although adjuvant therapy has been found to produce significant improvements in survival, the ability to predict the value of these treatments in individual patients is limited. The development of accurate predictors of treatment efficacy would permit better targeting of treatments, improving efficacy and reducing the morbidity and cost of treatment. It is essential that the value of predictive and prognostic factors be evaluated using standardized protocols in well-designed clinical studies with sufficient statistical power to detect clinically important differences. Successful integration of new technologies, such as tissue and expression microarrays and proteomics, will depend on careful design and analysis of clinical investigations. The value of sentinel lymph node biopsy and of sensitive assays for micrometastatic disease in lymph nodes and bone marrow should also be important priorities for clinical research.

Quality-of-life and late-effect evaluations should be judiciously integrated into selected clinical trials to better discern the acute and long-term influence of treatment on patients and their families. Interventions should be sought that will reduce side effects and improve quality of life. Decision aids and other techniques should be developed and evaluated for their ability to improve patients' involvement and understanding of treatment decisions.

Conclusions

During the past 10 years, substantial progress has been made in the treatment of breast cancer. For the first time, breast cancer mortality rates are decreasing in the United States. Refinements of adjuvant treatment have contributed to this advance.

Generally accepted prognostic and predictive factors include age, tumor size, lymph node status, histological tumor type, grade, mitotic rate, and hormonal receptor status. Novel technologies, such as tissue and expression microarrays and proteomics, hold exciting potential. Progress, however, will depend on proper design and analysis of clinical and pathological investigations.

Decisions regarding adjuvant hormonal therapy should be based on the presence of hormone receptor protein in tumor tissues. Adjuvant hormonal therapy should be offered to women whose tumors express hormone receptor protein. At present five years of tamoxifen is standard adjuvant hormone therapy; ovarian ablation represents an alternative option for selected premenopausal women. Adjuvant hormonal therapy should not be recommended to women whose tumors do not express hormone receptor protein.

Because adjuvant polychemotherapy improves survival, it should be recommended to the majority of women with localized breast cancer regardless of nodal, menopausal, or hormone receptor status. The inclusion of anthracyclines in adjuvant chemotherapy regimens produces a small but statistically significant improvement in survival over nonanthracycline-containing regimens.

Available data are currently inconclusive regarding the use of taxanes in adjuvant treatment of node-positive breast cancer. The use of adjuvant dose-intensive chemotherapy regimens in high-risk breast cancer and of taxanes in node-negative breast cancer should be restricted to randomized trials. Ongoing studies evaluating these treatment strategies should be supported to determine if they have a role in adjuvant treatment.

Studies to date have included few patients older than 70 years. There is a critical need for trials to evaluate the role of adjuvant chemotherapy in these women.

There is evidence that women with a high risk of loco-regional tumor recurrence after mastectomy benefit from postoperative radiotherapy. This high-risk group includes women with four or more positive lymph nodes or an advanced primary cancer. Currently, the role of post-mastectomy radiotherapy for patients with one to three positive lymph nodes remains uncertain and should be tested in a randomized controlled trial.

Individual patients differ in the importance they place on the risks and benefits of adjuvant treatments. Quality-of-life needs to be evaluated in selected randomized clinical trials to examine the impact of the major acute and long-term side effects of adjuvant treatments, particularly premature menopause, weight gain, mild memory loss, and fatigue. Methods to support shared decision-making between patients and their physicians have been successful in trials; they need to be tailored for diverse populations and should be tested for broader dissemination.

Consensus Development Panel

Patricia Eifel, M.D.

*Panel and Conference
Chairperson
Professor of Radiation Oncology
M.D. Anderson Cancer Center
University of Texas
Houston, Texas*

John A. Axelson, M.D., FACP

*Hematology and Oncology
Associates
Jackson, Michigan*

Jose Costa, M.D.

*Professor of Pathology
and Biology
Director of Anatomic Pathology
Deputy Director, Yale
Cancer Center
Vice Chairman, Department
of Pathology
Yale University School
of Medicine
New Haven, Connecticut*

John Crowley, Ph.D.

*Biostatistician
Fred Hutchinson Cancer
Research Center
Seattle, Washington*

Walter J. Curran, Jr., M.D.

*Professor and Chairman
Department of Radiation
Oncology
Thomas Jefferson
University Hospital
Philadelphia, Pennsylvania*

Ann Deshler, R.N.

*Administrative Director
Metro Minnesota CCOP
Institute for Research
and Education of
HealthSystem Minnesota
St. Louis Park, Minnesota*

Shirley Fulton, J.D., M.B.A.

*Superior Court Judge
Superior Court Judge Office
Charlotte, North Carolina*

Carolyn B. Hendricks, M.D.

*Medical Oncologist
Suburban Specialty Care
Physicians, P.C.
Bethesda, Maryland*

Margaret Kemeny, M.D.

*Surgeon
Chief of the Division of
Surgical Oncology
University Hospital and
Medical Center
State University of New York
at Stony Brook
Stony Brook, New York*

Alice B. Kornblith, Ph.D.

*Director of Outcomes Studies
Department of Pain Medicine
and Palliative Care and
Cancer Center
Beth Israel Medical Center
New York, New York*

Thomas A. Louis, Ph.D.

*Senior Statistical Scientist
The RAND Corporation
Arlington, Virginia*

Maurie Markman, M.D.

*Director, The Cleveland Clinic
Taussig Cancer Center
Chairman, Department
of Hematology and
Medical Oncology
The Lee and Jerome Burkons
Research Chair in Oncology
The Cleveland Clinic Foundation
Cleveland, Ohio*

Robert Mayer, M.D.
Professor of Medicine
Harvard Medical School
Vice Chair for Academic Affairs
Department of Adult Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Debra Roter, Dr.P.H.
Professor, Health Policy
and Management
School of Hygiene and
Public Health
Johns Hopkins University
Baltimore, Maryland

Speakers

Karen H. Antman, M.D.
Professor of Medicine
College of Physicians
and Surgeons of
Columbia University
Chief, Division of
Medical Oncology
Director, Herbert
Irving Comprehensive
Cancer Center
New York, New York

Jonas C. Bergh, M.D., Ph.D.
Professor of Clinical and
Molecular Oncology
Karolinska Institute and Hospital
Stockholm, Sweden

John L. Bryant, Ph.D.
Associate Professor
of Biostatistics
University of Pittsburgh
Director, Biostatistical Center
National Surgical Adjuvant
Breast and Bowel Project
Pittsburgh, Pennsylvania

Gary M. Clark, Ph.D.
Professor of Medicine
Baylor Breast Center
Baylor College of Medicine
Houston, Texas

Alan Coates, M.D., FRACP
International Breast Cancer
Study Group
Chief Executive Officer
Australian Cancer Society
Sydney, New South Wales
Australia

Jack Cuzick, Ph.D.
Professor of Epidemiology
Head, Department of
Mathematics, Statistics,
and Epidemiology
Imperial Cancer Research Fund
London, United Kingdom

Maria Grazia Daidone, Ph.D.
Unit 10 Determinants
of Prognosis and
Treatment Response
Department of Experimental
Oncology
Istituto Nazionale Tumori
Milan, Italy

Nancy E. Davidson, M.D.
Professor
Johns Hopkins Oncology Center
Johns Hopkins University
School of Medicine
Baltimore, Maryland

Christina Davies, MBChB, M.Sc.
ATLAS Coordinator
Clinical Trial Service Unit
Radcliffe Infirmary
University of Oxford
Oxford, United Kingdom

James J. Dignam, Ph.D.
Statistician
National Surgical Adjuvant
Breast and Bowel Project
Chicago, Illinois

Bernard Fisher, M.D.
Scientific Director
National Surgical Adjuvant
Breast and Bowel Project
Distinguished Service Professor
University of Pittsburgh
Pittsburgh, Pennsylvania

Patricia A. Ganz, M.D.

*Professor, UCLA Schools of
Medicine and Public Health
Director, Division of Cancer
Prevention and Control
Research*

Jonsson Comprehensive
Cancer Center
Los Angeles, California

Aron Goldhirsch, M.D.

*Chairman, Scientific Committee
International Breast Cancer
Study Group
Professor of Medical Oncology
Director, Division of Medical
Oncology
European Institute of Oncology
Milan, Italy*

Richard Gray, M.A., M.Sc.

*Director
Clinical Trials Unit
University of Birmingham
Medical School
Birmingham, United Kingdom*

I. Craig Henderson, M.D.

*Adjunct Professor of Medicine
University of California,
San Francisco
San Francisco, California*

**Gabriel N. Hortobagyi,
M.D., FACP**

*Professor and Chairman
Department of Breast
Medical Oncology
M.D. Anderson Cancer Center
University of Texas
Houston, Texas*

Amy S. Langer, M.B.A.

*Executive Director
National Alliance of Breast
Cancer Organizations
(NABCO)
New York, New York*

Mark Norman Levine, M.D.

*Professor of Medicine
McMaster University
Hamilton, Ontario, Canada*

Eleftherios P. Mamounas, M.D.

*Medical Director
Cancer Center
Aultman Hospital
Canton, Ohio*

Monica Morrow, M.D.

*Professor of Surgery, North-
western Memorial Hospital
Northwestern University
Medical School
Director, Lynn Sage Compre-
hensive Breast Program
Director of Cancer Department
American College of Surgeons
Chicago, Illinois*

Hyman B. Muss, M.D.

*Associate Director
Vermont Cancer Center
Professor of Medicine
University of Vermont
College of Medicine
Director of Hematology/
Oncology
Fletcher Allen Health Care
University of Vermont
Burlington, Vermont*

Larry Norton, M.D.

*Head, Division of Solid
Tumor Oncology
Norna S. Sarofim Chair
in Clinical Oncology
Memorial Sloan-Kettering
Cancer Center
New York, New York*

C. Kent Osborne, M.D.

*Professor
Baylor Breast Center
Baylor College of Medicine
Houston, Texas*

William P. Peters, M.D., Ph.D.

*Director and Chief
Executive Officer*
Barbara Ann Karmanos
Cancer Institute
Detroit, Michigan

Sir Richard Peto, F.R.S., M.Sc.

*Early Breast Cancer Trialists'
Collaborative Group
Secretariat*
*Professor of Medical Statistics
and Epidemiology Co-Director*
ICRF/MRC Clinical Trial Service
Unit and Epidemiological
Studies Unit
Radcliffe Infirmary
University of Oxford
Oxford, United Kingdom

Martine J. Piccart, M.D., Ph.D.

Chairman
Breast International Group
Head
Chemotherapy Department
Jules Bordet Institute
B-1000 Brussels, Belgium

Lori Pierce, M.D.

Associate Professor
Department of Radiation
Oncology
University of Michigan
Medical Center
Ann Arbor, Michigan

Peter Ravdin, M.D., Ph.D.

Associate Professor
Department of Medicine
Division of Medical Oncology
University of Texas Health
Science Center at
San Antonio
San Antonio, Texas

Stuart J. Schnitt, M.D.

*Associate Professor
of Pathology*
Harvard Medical School
Director of Surgical Pathology
Beth Israel Deaconess
Medical Center
Boston, Massachusetts

George W. Sledge, Jr., M.D.

*Ballvé-Lantero Professor
of Oncology*
Department of Medicine
Indiana University School
of Medicine
Indianapolis, Indiana

Eric P. Winer, M.D.

Associate Professor of Medicine
Department of Adult Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Norman Wolmark, M.D.

Chairman
National Surgical Adjuvant
Breast and Bowel Project
Chairman and Professor
Department of Human Oncology
Allegheny General Hospital
Pittsburgh, Pennsylvania

William C. Wood, M.D., FACS

*Joseph Brown Whitehead
Professor and Chairman*
Department of Surgery
Emory University School
of Medicine
Atlanta, Georgia

Planning Committee

Jeffrey Abrams, M.D.

*Planning Committee
Chairperson
Senior Investigator
Clinical Investigation Branch
Cancer Therapy Evaluation
Program
National Cancer Institute
Bethesda, Maryland*

Marietta Anthony, Ph.D.

*Director, Women's Health
Research
Department of Pharmacology
Georgetown University
Medical Center
Washington, DC*

Karen H. Antman, M.D.

*Professor of Medicine
College of Physicians
and Surgeons of
Columbia University
Chief, Division of Medical
Oncology
Director
Herbert Irving Comprehensive
Cancer Center
New York, New York*

Christine D. Berg, M.D.

*Director
Suburban Hospital
Cancer Center
Affiliated with Johns Hopkins
Oncology Center
Bethesda, Maryland*

John A. Bowersox

*Communications Specialist
Office of Medical Applications
of Research
Office of the Director
National Institutes of Health
Bethesda, Maryland*

John L. Bryant, Ph.D.

*Associate Professor
of Biostatistics
University of Pittsburgh
Director, Biostatistical Center
National Surgical Adjuvant
Breast and Bowel Project
Pittsburgh, Pennsylvania*

Alan Coates, M.D., FRACP

*Chief Executive Officer
International Breast Cancer
Study Group
Australian Cancer Society
Sydney, Australia*

Nancy E. Davidson, M.D.

*Professor
Johns Hopkins Oncology Center
Johns Hopkins University
School of Medicine
Baltimore, Maryland*

Patricia Eifel, M.D.

*Professor of Radiation Oncology
M.D. Anderson Cancer Center
University of Texas
Houston, Texas*

Jerry M. Elliott

*Program Analysis and
Management Officer
Office of Medical Applications
of Research
Office of the Director
National Institutes of Health
Bethesda, Maryland*

John H. Ferguson, M.D.

Potomac, Maryland

Patricia A. Ganz, M.D.

Professor
UCLA Schools of Medicine
and Public Health
Director
Division of Cancer Prevention
and Control Research
Jonsson Comprehensive
Cancer Center
Los Angeles, California

**Gabriel N. Hortobagyi,
M.D., FACP**

Professor and Chairman
Department of Breast
Medical Oncology
M.D. Anderson Cancer Center
University of Texas
Houston, Texas

Karen Eubanks Jackson

National President and Founder
Sisters Network, Inc.
Houston, Texas

Barnett S. Kramer, M.D., M.P.H.

Director
Office of Medical Applications
of Research
Office of the Director
National Institutes of Health
Bethesda, Maryland

Amy S. Langer, M.B.A.

Executive Director
National Alliance of Breast
Cancer Organizations
(NABCO)
New York, New York

Daniel J. O'Neal III, R.N., M.A.

Chief
Office of Science Policy
and Public Liaison
National Institute of
Nursing Research
National Institutes of Health
Bethesda, Maryland

Lori Pierce, M.D.

Associate Professor
Department of Radiation
Oncology
University of Michigan
Medical Center
Ann Arbor, Michigan

Charles R. Sherman, Ph.D.

Deputy Director
Office of Medical Applications
of Research
Office of the Director
National Institutes of Health
Bethesda, Maryland

Sheila E. Taube, Ph.D.

Associate Director
Cancer Diagnosis Program
Division of Cancer Treatment
and Diagnosis
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

Ann Thor, M.D.

Professor
Departments of Pathology
and Surgery
Northwestern University
Medical School
Evanston Northwestern
Healthcare
Evanston, Illinois

William C. Wood, M.D., FACS

Joseph Brown Whitehead
Professor and Chairman
Department of Surgery
Emory University School
of Medicine
Atlanta, Georgia

JoAnne Zujewski, M.D.

Senior Medical Oncologist
Division of Clinical Sciences
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

Conference Sponsors

National Cancer Institute

Richard D. Klausner, M.D.
Director

Office of Medical Applications of Research

Barnett S. Kramer, M.D., M.P.H.
Director

Conference Co-sponsors

National Institute of Nursing Research

Patricia A. Grady, Ph.D.,
R.N., FAAN
Director

Office of Research on Women's Health

Vivian W. Pinn, M.D.
Director

Bibliography

The following references were selected by the panel chair from references submitted with abstracts prepared by conference speakers. A more complete bibliography prepared by the National Library of Medicine at NIH was provided to the consensus panel for its consideration. The full NML bibliography is available at the following Website: http://www.nlm.nih.gov/pubs/cbm/adjuvant_therapy_breast_cancer.html.

Aebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J, Thürlimann B, et al., for the International Breast Cancer Study Group (IBCSG). Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? *Lancet* 2000;355:1869–74.

Altman DG, Lyman GH. Methodological challenges in the evaluation of prognostic factors in breast cancer. *Breast Cancer Res Treat* 1998; 52:289–303.

American Society of Clinical Oncology (ASCO) Expert Panel. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer: report of the American Society of Clinical Oncology Expert Panel. *J Clin Oncol* 1996;14:2843–77.

Bergh J. Results from a randomized adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy. *Proc Am Soc Clin Oncol* 1999;18:2a.

Bezwoda WR. Randomised, controlled trial of high dose chemotherapy versus standard dose chemotherapy for high risk, surgically treated, primary breast cancer. *Proc Am Soc Clin Oncol* 1999;18:2a.

Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. *J Clin Oncol* 1996;14:1718–29.

Boyer-Chamard A, Taylor TH, Anton-Culver H. Survival differences in breast cancer among racial/ethnic groups: a population-based study. *Cancer Detect Prev* 1999;23:463–73.

Breen N, Wesley MN, Merrill RM, Johnson K. The relationship of socio-economic status and access to minimum expected therapy among female breast cancer patients in the National Cancer Institute Black-White Cancer Survival Study. *Ethn Dis* 1999;9:111–25.

Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. *J Clin Oncol* 2000;18:2695–701.

Burstein HJ, Winer EP. Primary care for survivors of breast cancer. *N Eng J Med* 2000;343:1086–94.

Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status and survival in 24,740 breast cancer cases. *Cancer* 1989;63:181–7.

Chlebowski RT, Collyar DE, Somerfield MR, Pfister DG. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. *J Clin Oncol* 1999; 17:1939–55.

Curtis RE, Boice JD Jr, Stovall M, Bernstein L, Greenberg RS, Flannery JT, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. *N Eng J Med* 1992;326:1745–51.

Cuzick J, Stewart H, Rutqvist L, Houghton J, Edwards R, Redmond C, et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. *J Clin Oncol* 1994;12:447–53.

Desch CE, Hillner BE, Smith TJ, Retchin SM. Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes. *J Clin Oncol* 1993;11:777–82.

DiLeo A, Larsimon D, Beauduni M, et al. CMF or anthracycline-based adjuvant chemotherapy for node-positive (N+) breast cancer (BC) patients (PTS): 4 year results of a Belgian randomised clinical trial with predictive markers analysis. *Proc Am Soc Clin Oncol* 1998; 18:258a.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. *Lancet* 2000;355:1757–70.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Tamoxifen for early breast cancer: an overview of the randomised trials. *Lancet* 1998;351:1451–67.

Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. *Lancet* 1998b;352:930–42.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Ovarian ablation in early breast cancer: overview of the randomised trials. *Lancet* 1996;348:1189–96.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and surgery in early breast cancer: an overview of the randomized trials. *N Engl J Med* 1995;333:1444–55.

Extermann M, Balducci L, Lyman GH. What threshold for adjuvant therapy in older breast cancer patients? *J Clin Oncol* 2000;18:1709–17.

Fisher B, Anderson S, DeCillis A, Dimitrov N, Atkins JN, Fehrenbacher L, et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. *J Clin Oncol* 1999;17:3374–88.

Fisher B, Anderson S, Tan-Chiu E, et al. Tamoxifen and chemotherapy for axillary-node negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. *J Clin Oncol* (in press).

Fisher B, Anderson S, Wickerham DL, DeCillis A, Dimitrov N, Mamounas E, et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. *J Clin Oncol* 1997;15:1858–69.

Fisher B, Brown AM, Dimitrov NV, Poisson R, Redmond C, Margolese RG, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. *J Clin Oncol* 1990;8:1483–96.

Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. *J Clin Oncol* 1997;15:2483–93.

Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. *J Clin Oncol* 1998; 16:2672–85.

Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. *J Natl Cancer Inst* 1998;90:1371.

Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. *J Natl Cancer Inst* 1996;88:1529–42.

Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for node-negative breast cancer: updated findings. *J Natl Cancer Inst* [submitted].

Fisher B, Dignam J, Mamounas EP, Costantino JP, Wickerham DL, Redmond C, et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. *J Clin Oncol* 1996;14:1982–92.

Fisher B, Dignam J, Wolmark N, De Cillis A, Emir B, Wickerham DL, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. *J Natl Cancer Inst* 1997;89:1673–82.

Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, et al. Prognostic factors in breast cancer: College of American Pathologists Consensus Statement 1999. *Arch Pathol Lab Med* 2000;124:966–78.

Fleming ST, Rastogi A, Dmitrienko A, Johnson KD. A comprehensive prognostic index to predict survival based on multiple comorbidities: a focus on breast cancer. *Med Care* 1999;37:601–14.

Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. *J Natl Cancer Inst* 1999;91:1829–46.

Gianni L, Zambetti M, Moliterni A. Cardiac sequelae in operable breast cancer after CMF + doxorubicin + irradiation. *Proc Am Soc Clin Oncol* 1999;18:255.

Giuliano AE, Kelemen PR. Sophisticated techniques detect obscure lymph node metastases in carcinoma of the breast. *Cancer* 1998;83:391–3.

Goldhirsch A, Glick JH, Gelber RD, Senn HJ. Meeting highlights: International consensus panel on the treatment of primary breast cancer. *J Natl Cancer Inst* 1998;90:1601–8.

Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. *CA Cancer J Clin* 2000;50:7–33.

Harris JR, Halpin-Murphy P, McNeese M, Mendenhall NP, Morrow M, Robert NJ, et al. Consensus statement on postmastectomy radiation therapy. *Int J Radiat Oncol Biol Phys* 1999;44:989–90.

Henderson IC, Berry D, Demetri G, Cirrincione C, Goldstein L, Martino S, et al. Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with node-positive primary breast cancer (BC). *Proc Amer Soc Clin Oncol* 1998;16:390A.

Henderson IC, Gelman RS, Harris JR, Canellos GP. Duration of therapy in adjuvant chemotherapy trials. *NCI Monogr* 1986;95–8.

Hortobagyi GN. High-dose chemotherapy for primary breast cancer: facts versus anecdotes. *J Clin Oncol* 1999;17:25–9.

Hortobagyi GN, Buzdar AU, Theriault RL, Valero V, Frye D, Booser DJ, et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. *J Natl Cancer Inst* 2000;92:225–33.

Hutchins L, Green S, Ravdin P, et al. CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: first results of intergroup trial INT 0102. [abstract]. *Proc Am Soc Clin Oncol* 1998;17:1a.

Jakesz R, Hausmaninger H, Samonigg H, Kubista E, Depisch D, Fridrik M, et al. Comparison of adjuvant therapy with tamoxifen and goserelin vs CMF in premenopausal stage I and II hormone-responsive breast cancer patients: four-year results of Austrian Breast Cancer Study Group (ABC SG) Trial 5. [abstract]. *Proc Am Soc Clin Oncol* 1999;18:67a.

Kollias J, Elston CW, Ellis IO, Robertson JF, Blamey RW. Early-onset breast cancer-histopathological and prognostic considerations. *Br J Cancer* 1997;75:1318–23.

Kroman N, Jensen MB, Melbye M, Wohlfahrt J, Mouridsen HT. Should women be advised against pregnancy after breast-cancer treatment? *Lancet*. 1997;350:319–22.

Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. *J Clin Oncol* 1999;17:460–9.

Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. *J Clin Oncol* 1998;16:2651–8.

Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. *N Eng J Med* 1988;318:404–7.

Mamounas EP. NSABP Protocol B-27. Preoperative doxorubicin plus cyclophosphamide followed by preoperative or postoperative docetaxel. *Oncology* 1997;11:37–40.

Mansour EG, Ravdin PM, Dressler L. Prognostic factors in early breast cancer. *Cancer* 1994;74:381–400.

National Institutes of Health. Adjuvant chemotherapy of breast cancer. *Consens Dev Conf Summ* 1980;3:21–4.

NIH Consensus Development Panel. Treatment of early stage breast cancer. *J Natl Cancer Inst Monogr* 1992;11:137–42.

NIH Consensus Development Conference Statement: Adjuvant chemotherapy for breast cancer. September 9–11, 1985. *CA Cancer J Clin* 1986;36:42–7.

Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen. Danish Breast Cancer Cooperative Group. *Lancet* 1999;353:1641–8.

Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer. NSABP Protocol B-15. Submitted 2000.

Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. *J Natl Cancer Inst* 1998;90:1361–70.

Perloff M, Norton L, Korzun AH, Wood WC, Carey RW, Gottlieb A, et al. Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study. *J Clin Oncol* 1996;14:1589–98.

Perou C, Sörlie T, Eisen M, et al. Molecular portraits of human breast tumours. *Nature* 2000;406:747–52.

Peters WP, Rosner G, Vredenburgh J, et al. A prospective, randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes: preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13. *Proc Am Soc Clin Oncol* 1999;18:1a.

Ragaz J, Jackson SM, Le N, Plenderleith IH, Spinelli JJ, Basco VE, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. *N Engl J Med* 1997;337:956–62.

Rahman ZU, Hortobagyi GN, Buzdar AU, Champlin R. High-dose chemotherapy with autologous stem cell support in patients with breast cancer. *Cancer Treat Rev* 1998;24:249–63.

Ravdin P, Green S, Albain K, et al. Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen (T) alone. [abstract]. *Proc Am Soc Clin Oncol* 1998;17:97a.

Rea D, Poole C, Gray R. Adjuvant tamoxifen: how long before we know how long? *BMJ* 1998;316:1518–9.

Recht A, Gray R, Davidson NE, Fowble BL, Solin LJ, Cummings FJ, et al. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. *J Clin Oncol* 1999;17:1689–700.

Roche HH, Kerbrat P, Bonnetterre J, Fargeot P, Fumoleau P, Monnier A, et al. Complete hormonal blockade versus chemotherapy in premenopausal early-stage breast cancer patients with positive hormone-receptor (HR+) and 1-3 node-positive (N+) tumor: results of the FASG 06 trial. [abstract]. *Proc Am Soc Clin Oncol* 2000;19:72a.

Rodenhuis S, Richel DJ, van der Wall E, Schornagel JH, Baars JW, Konniq CC, et al. Randomised trial of high-dose chemotherapy and haematopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph node involvement. *Lancet* 1998;352:515–21.

Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. *J Cell Physiol* 2000;182:311–22.

Scottish Cancer Trials Breast Group (SCTBG) and ICRF Breast Unit, Guy's Hospital, London. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. *Lancet* 1993;341:1293–9.

Silvestrini R, Daidone MG, Luisi A, Boracchi P, Mezzetti M, Di Fronzo G, et al. Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. *J Clin Oncol* 1995; 13:697–704.

Sledge GW, Neuberger D, Ingle J, Martino S, Wood W. Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin + paclitaxel (A+T) as first-line therapy for metastatic breast cancer (MBC): an Intergroup trial. *Proc Amer Soc Clin Oncol* 1997;16:1a.

Stewart HJ, Forrest AP, Everington D, McDonald CC, Dewar JA, Hawkins RA, et al. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. *Br J Cancer* 1996;74:297–9.

Swedish Breast Cancer Cooperative Group (SBCCG). Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. *J Natl Cancer Inst* 1996;88:1543–9.

Sylvester R, Bartelink H, Rubens R. A reversal of fortune: practical problems in the monitoring and interpretation of an EORTC breast cancer trial. *Stat Med* 1994;13:1329–35.

Tejeda HA, Green SB, Trimble EL, Ford L, High JL, Ungerleider RS, et al. Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials. *J Natl Cancer Inst* 1996;88:812–6.

Thomas E, Buzdar A, Theriault R, Singletary S, Booser D, Valero V, et al. Role of paclitaxel in adjuvant therapy of operable breast cancer: preliminary results of prospective randomized clinical trial. *Proc Amer Soc Clin Oncol* 2000;19:74a.

- Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, et al. erbB2, p53, and efficacy of adjuvant therapy interactions in node-positive breast cancer. *Nat Cancer Inst* 1998;90:1346–1360
- Tormey DC, Gray R, Abeloff MD, Roseman DL, Gilchrist KW, Barylak EJ, et al. Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: An Eastern Cooperative Oncology Group trial. *J Clin Oncol* 1992;10:1848–56.
- Tormey DC, Gray R, Falkson HC. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. [Eastern Cooperative Oncology Group]. *J Natl Cancer Inst* 1996;88:1828–33.
- van Dam FS, Schagen SB, Muller MJ, Boogerd W, v d Wall E, Droogleeveer Fortuyn ME, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. *J Natl Cancer Inst* 1998;90:210–18.
- Vera R, Albanell J, Lirola JL, et al. HER2 overexpression as a predictor of survival in a trial comparing adjuvant FAC and CMF in breast cancer. *Proc Am Soc Clin Oncol* 1998;18:265a.
- Weiss RB, Rifkin RM, Stewart FM, Theriault RL, Williams LA, Herman AA, et al. High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study. *Lancet* 2000;355:999–1003.
- Wenger CR, Clark GM. S-phase fraction and breast cancer — a decade of experience. *Breast Cancer Res Treat* 1998;51:255–65.
- Winchester DP, Osteen RT, Menck HR. The National Cancer Data Base report on breast carcinoma characteristics and outcome in relation to age. *Cancer* 1996;78:1838–43.
- Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. *N Engl J Med* 1994;330:1253–9.



U.S. DEPARTMENT OF HEALTH
AND HUMAN SERVICES
Public Health Service
National Institutes of Health
Office of Medical Applications of Research
Building 31, Room 1B03
31 Center Drive, MSC 2082
Bethesda, MD 20892-2082

Official Business
Penalty for private use \$300

BULK RATE
Postage & Fees
PAID
DHHS/NIH
Permit No. G802